ClinicalTrials.gg
CompletedNCT01080391Updated Sep 21, 2022Results posted

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

A Phase 3 interventional study of Dexamethasone and Lenalidomide in Relapsed Multiple Myeloma, sponsored by Amgen. Completed at 127 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-21.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
792
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.

Enrollment
4th of 113
792 · median 54
Started
2010
with 2 others
Phase 3
15 of 113
1 open now
Registered
10th of 113
by date
Lead sponsor
21 of 113
Amgen

Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 4th largest by enrollment, is one of 3 that started in 2010, is one of 15 in phase 3, and was the 10th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carfilzomib

carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing carfilzomib in Multiple Myeloma, or all of them as a file.
02

Study summary

The primary objective was to compare progression-free survival in adults with relapsed multiple myeloma who are receiving CRd vs participants receiving Rd in a randomized multicenter setting.

Read the detailed description

This is a Phase 3, randomized, open-label, multicenter study comparing two treatment regimens for adults with relapsed multiple myeloma. Eligible subjects will be randomized in a 1:1 ratio to receive either the control Rd or CRd. Randomization will be stratified by β2 microglobulin levels (\< vs ≥ 2.5 mg/L), prior bortezomib (no vs yes), and prior lenalidomide (no vs yes). Participants will receive the treatment determined by randomization in 28-day cycles until disease progression or unacceptable toxicity (whichever occurs first).

03

Conditions studied

  • Relapsed Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Symptomatic multiple myeloma
  2. , as defined by one or more of the following (assessed within 21 days prior to randomization):

    • Serum M-protein ≥ 0.5 g/dL
    • Urine Bence-Jones protein ≥ 200 mg/24 hours
    • For immunoglobulin A (IgA) patients whose disease can only be reliably measured by serum quantitative immunoglobulin (qIgA) ≥ 750 mg/dL (0.75 g/dL)
  3. Prior treatment with at least one, but no more than three, regimens for multiple myeloma
  4. Documented relapse or progressive disease on or after any regimen
  5. Achieved a response to at least one prior regimen
  6. Age ≥ 18 years
  7. ≥ 3 months
  8. (ECOG) performance status 0-2
  9. Adequate hepatic function, with serum (ALT) ≤ 3.5 times the and serum direct ≤ 2 mg/dL (34 µmol/L) within 21 days prior to randomization
  10. ≥ 1.0 × 10\^9/L within 21 days prior to randomization
  11. ≥ 8 g/dL (80 g/L) within 21 days prior to randomization
  12. count ≥ 50 × 10\^9/L (≥ 30 × 10\^9/L if myeloma involvement in the bone marrow is > 50%) within 21 days prior to randomization
  13. (CrCl) ≥ 50 mL/minute within 21 days prior to randomization
  14. Written in accordance with federal, local, and institutional guidelines
  15. Females of must agree to ongoing pregnancy testing and to practice
  16. Male subjects must agree to practice contraception

Exclusion criteria

Exclusion Criteria:

  1. If previously treated with bortezomib (alone or in combination), progression during treatment
  2. If previously treated with a lenalidomide and dexamethasone (len/dex) combination:

    • Progression during the first 3 months of initiating treatment
    • Any progression during treatment if the len/dex combination was the subject's most recent
  3. Discontinuation of previous lenalidomide or dexamethasone due to intolerance; subjects intolerant to bortezomib are not excluded
  4. Prior carfilzomib treatment
  5. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
  6. Waldenström's macroglobulinemia or IgM myeloma
  7. Plasma cell leukemia (> 2.0 × 10\^9/L circulating plasma cells by standard differential)
  8. Chemotherapy or agent within 3 weeks prior to randomization or antibody therapy within 6 weeks prior to randomization
  9. Radiotherapy to multiple sites or immunotherapy/antibody therapy within 28 days prior to randomization; localized radiotherapy to a single site within 7 days prior to randomization
  10. therapy at a dose equivalent to dexamethasone > 4 mg/day within 21 days prior to randomization
  11. Pregnant or lactating females
  12. Major surgery within 21 days prior to randomization
  13. Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to randomization
  14. Known infection
  15. Active or C infection
  16. Myocardial infarction within 4 months prior to randomization, New York Hear Association () Class III or IV heart failure, uncontrolled angina, history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless subject has a pacemaker
  17. Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to randomization
  18. Other , including myelodysplastic syndromes (MDS), within the past 3 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder or benign tumors of the adrenal or pancreas
  19. Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to randomization
  20. Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)
  21. to any of the required concomitant drugs or supportive treatments, including to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment
  22. Ongoing graft-vs-host disease
  23. Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomization
  24. Any other medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
792 participants (actual)

Study arms

  • Active comparator
    Lenalidomide and Dexamethasone (Rd)

    Treatment was administered in cycles repeated every 28 days. Lenalidomide 25 mg was administered orally on days 1 to 21 and dexamethasone 40 mg was administered orally or IV on days 1, 8, 15, and 22.

    Drug: Dexamethasone · Drug: Lenalidomide

  • Experimental
    Carfilzomib, Lenalidomide, and Dexamethasone (CRd)

    Treatment was administered in cycles every 28 days. Carfilzomib 20 mg/m² was administered intravenously (IV) on days 1 and 2 of cycle 1, escalating to 27 mg/m² on days 8, 9, 15, and 16 of cycle 1 and continuing on days 1, 2, 8, 9, 15, and 16 of cycle 2 through cycle 12 and then from cycle 13 through cycle 18, 27 mg/m² on days 1, 2, 15, and 16. Lenalidomide 25 mg was administered orally on days 1 to 21 from cycle 1 through cycle 18 and from cycle 19 and higher. Dexamethasone 40 mg was administered orally or IV on days 1, 8, 15, and 22 from cycle 1 through cycle 18 and from cycle 19 and higher.

    Drug: Dexamethasone · Drug: Lenalidomide · Drug: Carfilzomib

Interventions

  • 40 mg orally or IV on days 1, 8, 15, 22

  • 25 mg orally on days 1-21

    Also known as: Revlimid

  • 20 mg/m², 27 mg/m² intravenously

    Also known as: PR-171, Kyprolis®

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    Kaplan-Meier estimate of median time from randomization to progressive disease (PD) or all-cause death. PD was assessed using International Myeloma Working Group-Uniform Response Criteria (IMWG-URC). One or more conditions were required to meet PD: 2 consecutive rising serum or urine M-protein from central lab; documented new bone lesion(s) or soft tissue plasmacytoma(s) or increased size of existing bone lesion(s) or plasmacytoma(s); or confirmed hypercalcemia due solely to plasma cell proliferative disorder (local lab greater than 11.5 mg/dL on 2 separate occasions). Censoring conditions (censoring dates) were: no post-baseline disease assessment (DA) (randomization date); started non-protocol systemic anticancer treatment before PD or death (last DA date before such treatment); died or had PD after more than 1 missed DA (last DA date without PD before the first missed visit); or were alive and without documentation of PD, including lost to follow-up without PD (last DA date).

    Time frame: From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.

Secondary outcomes

  1. Overall Survival

    Overall survival (OS) was defined as the duration from randomization to death due to any cause. Participants who were still alive were censored at the date when the participant was last known to be alive or the data cutoff date, whichever occurred earlier.

    Time frame: From randomization through the data cutoff date of 28 April 2017 for the final analysis of overall survival; median follow up time was 67.1 months in each treatment group.

  2. Overall Response Rate

    Overall response rate is defined as the percentage of participants who achieved either a confirmed stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) as their best response based on the Independent Review Committee (IRC) assessed response outcome. Response was determined using the International Myeloma Working Group - Uniform Response Criteria (IMWG-URC).

    Time frame: From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.

  3. Disease Control Rate

    Disease control rate was defined as the percentage of participants who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), minimal response (MR), or stable disease (SD) lasting ≥ 8 weeks according to International Myeloma Working Group - Uniform Response Criteria (IMWG-URC) (MR was determined using European Group for Blood and Marrow Transplantation criteria).

    Time frame: From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.

  4. Duration of Response

    Duration of response (DOR) was calculated for participants who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). Duration of response was defined as the time in months from the initial start of response (PR or better) to the earlier of documented progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for PFS.

    Time frame: From randomization through the data cutoff date of 16 June 2014. Longest follow-up time was approximately 42 months.

  5. Duration of Disease Control

    Duration of disease control (DDC) was calculated for participants who achieved disease control. DDC was defined as the time in months from randomization to the earlier of documented progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for PFS.

    Time frame: From randomization through the data cutoff date of 16 June 2014. Longest follow-up time was approximately 46 months.

  6. Quality of Life Core Module (QLQ-C30) Global Health Status/Quality of Life Scores

    Health-related quality of life was assessed with the use of the European Organization for Research and Treatment of Cancer Quality of Life Core Module (QLQ-C30) questionnaire, a validated instrument in multiple myeloma patients. Scores range from 0 to 100, with higher scores indicating better health related quality of life.

    Time frame: Cycle 1 Day 1 (Baseline), Day 1 of Cycles 3, 6, 12, 18

07

Results

Posted Jul 8, 2015

Participant flow

Participants were enrolled from 14 July 2010 to 15 March 2012. The primary analysis was conducted using a data cut-off date of 16 June 2014 and the final safety analysis after last subject last visit date (05 December 2017).

Participant flow — Overall Study
MilestoneLenalidomide and Dexamethasone (Rd)Carfilzomib, Lenalidomide, and Dexamethasone (CRd)
Started396396
Treated389392
Completed389392
Not completed74
Withdrew: Randomized but not treated74

Outcome measures

PrimaryProgression-free Survival (PFS)

Kaplan-Meier estimate of median time from randomization to progressive disease (PD) or all-cause death. PD was assessed using International Myeloma Working Group-Uniform Response Criteria (IMWG-URC). One or more conditions were required to meet PD: 2 consecutive rising serum or urine M-protein from central lab; documented new bone lesion(s) or soft tissue plasmacytoma(s) or increased size of existing bone lesion(s) or plasmacytoma(s); or confirmed hypercalcemia due solely to plasma cell proliferative disorder (local lab greater than 11.5 mg/dL on 2 separate occasions). Censoring conditions (censoring dates) were: no post-baseline disease assessment (DA) (randomization date); started non-protocol systemic anticancer treatment before PD or death (last DA date before such treatment); died or had PD after more than 1 missed DA (last DA date without PD before the first missed visit); or were alive and without documentation of PD, including lost to follow-up without PD (last DA date).

Time frame:
From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.
Reported as:
Median · months
Progression-free Survival (PFS)
monthsLenalidomide and Dexamethasone (Rd)Carfilzomib, Lenalidomide, and Dexamethasone (CRd)
Progression-free Survival (PFS)17.6 (15.0 to 20.6)26.3 (23.3 to 30.5)
Statistical analysis
  • Lenalidomide and Dexamethasone (Rd) vs Carfilzomib, Lenalidomide, and Dexamethasone (CRd) · Log Rank · p = < 0.0001 (Analysis was stratified by β2 microglobulin levels (\< 2.5 mg/L vs. ≥ 2.5 mg/L), prior bortezomib (no vs. yes), and prior lenalidomide (no vs. yes)) · Hazard ratio (hr): 0.690 · 95% CI 0.570 to 0.834The stopping boundary for this analysis was 0.0127 based on 1-sided significance level (O'Brien-Fleming with Lan-DeMets spending function).
SecondaryOverall Survival

Overall survival (OS) was defined as the duration from randomization to death due to any cause. Participants who were still alive were censored at the date when the participant was last known to be alive or the data cutoff date, whichever occurred earlier.

Time frame:
From randomization through the data cutoff date of 28 April 2017 for the final analysis of overall survival; median follow up time was 67.1 months in each treatment group.
Reported as:
Median · months
Overall Survival
monthsLenalidomide and Dexamethasone (Rd)Carfilzomib, Lenalidomide, and Dexamethasone (CRd)
Overall Survival40.4 (33.6 to 44.4)48.3 (42.4 to 52.8)
Statistical analysis
  • Lenalidomide and Dexamethasone (Rd) vs Carfilzomib, Lenalidomide, and Dexamethasone (CRd) · Log Rank · p = 0.0045 · Hazard ratio (hr): 0.794 · 95% CI 0.667 to 0.945Analysis was stratified by β2 microglobulin levels (\< 2.5 mg/L vs. ≥ 2.5 mg/L), prior bortezomib (no vs. yes), and prior lenalidomide (no vs. yes).
SecondaryOverall Response Rate

Overall response rate is defined as the percentage of participants who achieved either a confirmed stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) as their best response based on the Independent Review Committee (IRC) assessed response outcome. Response was determined using the International Myeloma Working Group - Uniform Response Criteria (IMWG-URC).

Time frame:
From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.
Reported as:
Number · percentage of participants
Overall Response Rate
percentage of participantsLenalidomide and Dexamethasone (Rd)Carfilzomib, Lenalidomide, and Dexamethasone (CRd)
Overall Response Rate66.7 (61.8 to 71.3)87.1 (83.4 to 90.3)
Statistical analysis
  • Lenalidomide and Dexamethasone (Rd) vs Carfilzomib, Lenalidomide, and Dexamethasone (CRd) · Cochran-Mantel Haenszel chi-square test · p = < 0.0001 · Odds ratio (or): 3.472 · 95% CI 2.411 to 5.001The odds ratio and 95% CI were estimated using the Mantel-Haenszel method.
SecondaryDisease Control Rate

Disease control rate was defined as the percentage of participants who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), minimal response (MR), or stable disease (SD) lasting ≥ 8 weeks according to International Myeloma Working Group - Uniform Response Criteria (IMWG-URC) (MR was determined using European Group for Blood and Marrow Transplantation criteria).

Time frame:
From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.
Reported as:
Number · percentage of participants
Disease Control Rate
percentage of participantsLenalidomide and Dexamethasone (Rd)Carfilzomib, Lenalidomide, and Dexamethasone (CRd)
Disease Control Rate87.1 (83.4 to 90.3)92.7 (89.7 to 95.0)
Statistical analysis
  • Lenalidomide and Dexamethasone (Rd) vs Carfilzomib, Lenalidomide, and Dexamethasone (CRd) · Cochran-Mantel Haenszel chi-square test · p = 0.0044 · Odds ratio (or): 1.897 · 95% CI 1.17 to 3.08The odds ratio and 95% CI were estimated using the Mantel-Haenszel method.
SecondaryDuration of Response

Duration of response (DOR) was calculated for participants who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). Duration of response was defined as the time in months from the initial start of response (PR or better) to the earlier of documented progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for PFS.

Time frame:
From randomization through the data cutoff date of 16 June 2014. Longest follow-up time was approximately 42 months.
Reported as:
Median · months
Duration of Response
monthsLenalidomide and Dexamethasone (Rd)Carfilzomib, Lenalidomide, and Dexamethasone (CRd)
Duration of Response21.2 (16.7 to 25.8)28.6 (24.9 to 31.3)
SecondaryDuration of Disease Control

Duration of disease control (DDC) was calculated for participants who achieved disease control. DDC was defined as the time in months from randomization to the earlier of documented progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for PFS.

Time frame:
From randomization through the data cutoff date of 16 June 2014. Longest follow-up time was approximately 46 months.
Reported as:
Median · months
Duration of Disease Control
monthsLenalidomide and Dexamethasone (Rd)Carfilzomib, Lenalidomide, and Dexamethasone (CRd)
Duration of Disease Control18.9 (16.6 to 22.2)28.7 (24.4 to 31.6)
SecondaryQuality of Life Core Module (QLQ-C30) Global Health Status/Quality of Life Scores

Health-related quality of life was assessed with the use of the European Organization for Research and Treatment of Cancer Quality of Life Core Module (QLQ-C30) questionnaire, a validated instrument in multiple myeloma patients. Scores range from 0 to 100, with higher scores indicating better health related quality of life.

Time frame:
Cycle 1 Day 1 (Baseline), Day 1 of Cycles 3, 6, 12, 18
Reported as:
Mean · scores on a scale
Quality of Life Core Module (QLQ-C30) Global Health Status/Quality of Life Scores
scores on a scaleLenalidomide and Dexamethasone (Rd)Carfilzomib, Lenalidomide, and Dexamethasone (CRd)
Cycle 1 Day 1 (Baseline)58.1 ± 21.758.3 ± 21.7
Cycle 3, Day 156.8 ± 19.459.9 ± 20.4
Cycle 6, Day 158.9 ± 19.762.5 ± 20.1
Cycle 12, Day 157.3 ± 19.762.7 ± 19.6
Cycle 18, Day 159.9 ± 18.864.3 ± 19.2

Adverse events

Collected over From the first dose of study drug to 30 days after the last dose or initiation of new anticancer therapy, whichever occurred first. Median treatment duration was 57 and 88 weeks in each treatment group respectively, with a maximum of 338 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenalidomide and Dexamethasone (Rd)—221/389 (56.8%)358/389 (92%)
Carfilzomib, Lenalidomide, and Dexamethasone (CRd)—256/392 (65.3%)370/392 (94.4%)
Most frequent serious events
Showing 10 of 375
Most frequent serious events
EventLenalidomide and Dexamethasone (Rd)Carfilzomib, Lenalidomide, and Dexamethasone (CRd)
PneumoniaInfections and infestations52/38967/392
Respiratory tract infectionInfections and infestations8/38916/392
PyrexiaGeneral disorders12/38915/392
PyrexiaGeneral disorders9/38914/392
Pulmonary embolismRespiratory, thoracic and mediastinal disorders8/38912/392
BronchitisInfections and infestations11/3899/392
AnaemiaBlood and lymphatic system disorders10/3898/392
Cerebrovascular accidentNervous system disorders10/3894/392
DiarrhoeaGastrointestinal disorders9/3897/392
Atrial fibrillationCardiac disorders8/3899/392
Most frequent other events
Showing 10 of 77
Most frequent other events
EventLenalidomide and Dexamethasone (Rd)Carfilzomib, Lenalidomide, and Dexamethasone (CRd)
DiarrhoeaGastrointestinal disorders143/389170/392
AnaemiaBlood and lymphatic system disorders154/389166/392
NeutropeniaBlood and lymphatic system disorders133/389157/392
FatigueGeneral disorders124/389132/392
FatigueGeneral disorders119/389128/392
CoughRespiratory, thoracic and mediastinal disorders70/389116/392
ThrombocytopeniaBlood and lymphatic system disorders94/389115/392
Upper respiratory tract infectionInfections and infestations81/389115/392
HypokalaemiaMetabolism and nutrition disorders58/389114/392
PyrexiaGeneral disorders80/389110/392

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lenalidomide and Dexamethasone (Rd)Carfilzomib, Lenalidomide, and Dexamethasone (CRd)Total
Mean64.5 ± 9.0463.3 ± 9.2163.9 ± 9.14
Sex: Female, Male
Sex: Female, Male(Participants)Lenalidomide and Dexamethasone (Rd)Carfilzomib, Lenalidomide, and Dexamethasone (CRd)Total
Female164181345
Male232215447
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lenalidomide and Dexamethasone (Rd)Carfilzomib, Lenalidomide, and Dexamethasone (CRd)Total
American Indian or Alaska Native101
Asian/Native Hawaiian or Pacific Islander314
Black or African American111223
White377377754
Other4610
Serum β2 Microglobulin
Serum β2 Microglobulin(Participants)Lenalidomide and Dexamethasone (Rd)Carfilzomib, Lenalidomide, and Dexamethasone (CRd)Total
< 2.5 mg/L7777154
≥ 2.5 mg/L319319638
Prior Bortezomib Exposure
Prior Bortezomib Exposure(Participants)Lenalidomide and Dexamethasone (Rd)Carfilzomib, Lenalidomide, and Dexamethasone (CRd)Total
Yes261261522
No135135270
Prior Lenalidomide Exposure
Prior Lenalidomide Exposure(Participants)Lenalidomide and Dexamethasone (Rd)Carfilzomib, Lenalidomide, and Dexamethasone (CRd)Total
Yes7880158
No318316634
08

Study locations

127 sites
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • Providence St. Joseph Medical Center
    Burbank, California 91505, United States
  • St. Jude Hospital Yorba Linda dba; St. Joseph Heritage Healthcare
    Santa Rosa, California 94503, United States
  • Stanford University
    Stanford, California 94305, United States
  • Colorado Blood Cancer Institute
    Denver, Colorado 80218, United States
  • Cancer and Blood Disease Center
    Lecanto, Florida 34461, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Indiana University Health Melvin and Bren Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • University of Kansas Cancer Center
    Kansas City, Kansas 66160, United States
  • The University of Michigan - Comprehensive Cancer Center
    Ann Arbor, Michigan 48109, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • NYU Clinical Cancer Center
    New York, New York 10016, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • Associates in Oncology and Hematology
    Chattanooga, Tennessee 37404, United States
  • The Don & Sybil Harrington Cancer Center
    Amarillo, Texas 79106, United States
  • Baylor Sammons Cancer Center
    Dallas, Texas 75246, United States
  • UT Southwestern Medical Center at Dallas
    Dallas, Texas 75390-8565, United States
  • The University of Texas, MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Scott and White Memorial Hospital
    Temple, Texas 76508, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • Froedtert & Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Medizinische Universitat Wien
    Wien, 1090, Austria
  • Wilhelminspital der Stadt Wien, Zentrum fur Onkologie und Hamatologie
    Wien, 1171, Austria
  • Ziekenhuisnetwerk Antwerpen - AZ Stuivenberg
    Antwerpen, 2060, Belgium
  • AZ Sint-Jan AV
    Brugge, 8000, Belgium
  • UZ Brussel
    Brussels, 1090, Belgium
  • Institut Jules Bordet
    Bruxelles, 1000, Belgium
  • Cliniques Universitaires Saint-Luc
    Bruxelles, 1200, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • University Multiprofile Hospital for Active Treatment, "Dr. Georgi Stranski"
    Pleven, 5800, Bulgaria
  • University Multiprofile Hospital for Active Treatment "Sveti Georgi"
    Plovdiv, 4002, Bulgaria
  • Military Medical Academy Multiprofile Hospital for Active Treatment
    Sofia, 1606, Bulgaria
  • Specialized Hospital for Active Treatment of Hematological Diseases
    Sofia, 1756, Bulgaria
  • Multiprofile Hospital for Active Treatment "Sveta Marina"
    Varna, 9010, Bulgaria
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
  • University of Alberta, Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • Cancer Care Manitoba
    Winnipeg, Manitoba R3E 0V9, Canada
  • General Hospital, Health Sciences Centre
    St John's, Newfoundland and Labrador A1B 3V6, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • McGill University Health Center, Royal Victoria Hospital
    Montreal, Quebec H3A 1A1, Canada
  • Sir Mortimer B. Davis - Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • University Hospital Brno, Department of Internal Medicine - Hematooncology
    Brno, 625 00, Czechia
  • University Hospital Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • University Hospital Olomouc
    Olomouc, 775 20, Czechia
  • University Hospital Kralovske Vinohrady - Prague
    Praha 10, 100 34, Czechia
  • General University Hospital Prague
    Praha 2, 128 08, Czechia
  • Hospital Antoine Beclere
    Clamart, 92140, France
  • Clinique Victor Hugo - Centre Jean Bernard
    Le Mans, 72000, France
  • Hopital Claude Huriez
    Lille, 59037, France
  • CH de Mulhouse, Hopital Emile Muller
    Mulhouse, 68070, France
  • CHU Nantes Hotel Dieu
    Nantes, 44093, France
  • Hopital Saint-Antoine
    Paris, 75012, France
  • Groupe Hospitalier Necker - Enfants Malades
    Paris, 75015, France
  • Cancer Institut Universitaire de Toulouse-Oncopole (iUCT)
    Toulouse, 31100, France
  • Hopitaux de Brabois
    Vandoeuvre-Les-Nancy, 54511, France
  • University of Dusseldorf
    Dusseldorf, 40225, Germany
  • Krankenhaus Nordwest
    Frankfurt am Main, 60488, Germany
  • University of Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Universitat Heidelberg
    Heidelberg, 69120, Germany
  • Stiftungsklinikum Mittelrhein
    Koblenz, 56068, Germany
  • LMU Klinikum der Universitat
    Munchen, 81377, Germany
  • Universitatsklinikum Munster
    Munster, 48129, Germany
  • Universitatsklinikum Wurzburg
    Wurzburg, 97080, Germany
  • Alexandra Hospital
    Athens, 11528, Greece
  • University General Hospital of Patras
    Patras, 26500, Greece
  • St. Istvan and St. Laszlo Hospital of Budapest
    Budapest, H-1097, Hungary
  • University of Debrecen, Medical and Health Science Center
    Debrecen, H-4032, Hungary
  • Petz Aladar County Teaching Hospital
    Gyor, H-9032, Hungary
  • Bekes County Pandy Kalman Hospital
    Gyula, H-5700, Hungary
  • Kaposi Mor County Teaching Hospital
    Kaposvar, H-7400, Hungary
  • University of Pecs
    Pecs, H-7624, Hungary
  • University of Szeged, Albert Szent-Gyorgi Clinical Center
    Szeged, H-6720, Hungary
  • Rambam Medical Center
    Haifa, 31096, Israel
  • Hadassah Medical Center, Ein Kerem
    Jerusalem, 91120, Israel
  • Western Gailee Hospital - Nahariya
    Nahariya, 22100, Israel
  • Rabin Medical Center
    Petach Tikva, 49100, Israel
  • The Chaim Sheba Medical Center
    Ramat Gan, 52621, Israel
  • Kaplan Medical Center
    Rehovot, 76100, Israel
  • Azienda Ospedallera Niguarda Ca Granda
    Milano, 20162, Italy
  • Azienda Ospedllero Maggiore della Carita
    Novara, 28100, Italy
  • Azienda Ospedaliera Pisana Ospendale Santa Chiara - Main
    Pisa, 56216, Italy
  • Ospedale S. Eugenio
    Roma, 00144, Italy
  • Azienda Ospedaliera Citta della Salute e della Scienza di Torino
    Torino, 10126, Italy
  • Erasmus MC, Department of Haematology
    Rotterdam, 3015 CE, Netherlands
  • University Clinical Centre, Department of Hematologii Transplantologii
    Gdansk, 80-952, Poland
  • Samodzielny Publ. Szp. Wojewodzki w Gorzow Wlkp.
    Gorzow Wielkopolski, 66-400, Poland
  • Independent Public Teaching Hospital of Medical University of Silesia in Katowice
    Katowice, 40-027, Poland
  • Nicolaus Copernicus Memorial Provincial Specialist Hospital in Lodz
    Lodz, 93-510, Poland
  • Szpital Wojewwodzki im. dr Ludwika Rydygiera w Suwalkach
    Suwalki, 16-400, Poland
  • Nicolaus Copernicus Municipal Specialist Hospital
    Torun, 87-100, Poland
  • Maria Sklodowska-Curie Institute of Oncology
    Warszawa, 02-781, Poland
  • Zamojski Non-Public Hospital
    Zamosc, 22-400, Poland
  • Fundeni Clinical Institute, "Stefan Berceanu" Center for Hematology and Bone Marrow Transplantation
    Bucharest, 022328, Romania
  • Coltea Clinical Hospital
    Bucharest, 030-171, Romania
  • Bucharest University Emergency Hospital
    Bucharest, 050098, Romania
  • Regional Institute of Iasi
    Iasi, 700483, Romania
  • State Medical Institution Komi Republican Oncological Center
    Syktyvkar, Komi Republic 167904, Russian Federation
  • First Republican Clinical Hospital under the Ministry of Healthcare of the Republic of Udmurtia
    Izhevsk, 426039, Russian Federation

Showing the first 100 of 127 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Dimopoulos M, Wang M, Maisnar V, Minarik J, Bensinger W, Mateos MV, Obreja M, Blaedel J, Moreau P. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol Oncol. 2018 Apr 4;11(1):49. doi: 10.1186/s13045-018-0583-7. PubMed 29615082 ↗
  • Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Spicka I, Masszi T, Hajek R, Rosinol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016 Sep 1;128(9):1174-80. doi: 10.1182/blood-2016-03-707596. Epub 2016 Jul 20. PubMed 27439911 ↗
  • Dimopoulos MA, Stewart AK, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Ro S, Aggarwal S, Moreau P, Palumbo A. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer J. 2017 Apr 21;7(4):e554. doi: 10.1038/bcj.2017.31. PubMed 28430175 ↗
  • Dimopoulos MA, Stewart AK, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Palumbo A, Obreja M, Aggarwal S, Moreau P. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol. 2017 May;177(3):404-413. doi: 10.1111/bjh.14549. Epub 2017 Feb 17. PubMed 28211560 ↗
  • Jakubowiak AJ, Campioni M, Benedict A, Houisse I, Tichy E, Giannopoulou A, Aggarwal SK, Barber BL, Panjabi S. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. J Med Econ. 2016 Nov;19(11):1061-1074. doi: 10.1080/13696998.2016.1194278. Epub 2016 Jun 16. PubMed 27224006 ↗
  • Stewart AK, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel DS, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Buchanan J, Cocks K, Yang X, Xing B, Zojwalla N, Tonda M, Moreau P, Palumbo A. Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. J Clin Oncol. 2016 Nov 10;34(32):3921-3930. doi: 10.1200/JCO.2016.66.9648. PubMed 27601539 ↗
  • Chari A, Stewart AK, Russell SD, Moreau P, Herrmann J, Banchs J, Hajek R, Groarke J, Lyon AR, Batty GN, Ro S, Huang M, Iskander KS, Lenihan D. Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. Blood Adv. 2018 Jul 10;2(13):1633-1644. doi: 10.1182/bloodadvances.2017015545. PubMed 29991494 ↗
  • Facon T, Niesvizky R, Mateos MV, Siegel D, Rosenbaum C, Bringhen S, Weisel K, Ho PJ, Ludwig H, Kumar S, Wang K, Obreja M, Yang Z, Klippel Z, Mezzi K, Goldrick A, Tekle C, Dimopoulos MA. Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. Blood Adv. 2020 Nov 10;4(21):5449-5459. doi: 10.1182/bloodadvances.2020001965. PubMed 33166401 ↗
  • Hari P, Mateos MV, Abonour R, Knop S, Bensinger W, Ludwig H, Song K, Hajek R, Moreau P, Siegel DS, Feng S, Obreja M, Aggarwal SK, Iskander K, Goldschmidt H. Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes. Leukemia. 2017 Dec;31(12):2630-2641. doi: 10.1038/leu.2017.122. Epub 2017 Apr 25. PubMed 28439109 ↗
  • Leleu X, Martin TG, Einsele H, Lyons RM, Durie BGM, Iskander KS, Ailawadhi S. Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):9-22. doi: 10.1016/j.clml.2018.08.016. Epub 2018 Sep 5. PubMed 30287200 ↗
  • Mateos MV, Goldschmidt H, San-Miguel J, Mikhael J, DeCosta L, Zhou L, Obreja M, Blaedel J, Szabo Z, Leleu X. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials. Hematol Oncol. 2018 Apr;36(2):463-470. doi: 10.1002/hon.2499. Epub 2018 Feb 15. PubMed 29446103 ↗
  • Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, San-Miguel J, Obreja M, Blaedel J, Stewart AK. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2018 Mar 10;36(8):728-734. doi: 10.1200/JCO.2017.76.5032. Epub 2018 Jan 17. PubMed 29341834 ↗
  • Weisel K, Mateos MV, Gay F, Delforge M, Cook G, Szabo Z, Desgraz R, DeCosta L, Moreau P. Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR. Leukemia. 2021 Jun;35(6):1732-1744. doi: 10.1038/s41375-020-01049-5. Epub 2020 Oct 16. PubMed 33067574 ↗
  • Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6. PubMed 25482145 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2010 to primary completion in Jun 2014, 47 months.

Results were first posted in Jul 2015, 1 year after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 47 months is close to that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2010
First posted
Mar 4, 2010
StartActual
Jul 14, 2010
Primary completionActual
Jun 16, 2014
CompletionActual
Dec 5, 2017
Results first posted
Jul 8, 2015
Last update
Sep 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01080391
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Mar 4, 2010
Start date
Jul 14, 2010
Primary completion
Jun 16, 2014
Completion
Dec 5, 2017
Results posted
Jul 8, 2015
Last update
Sep 21, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carfilzomib

Start the discussion